DE1966436C3 - Verwendung einer Antigen-Immunserum-Kombination als Impfstoff - Google Patents
Verwendung einer Antigen-Immunserum-Kombination als ImpfstoffInfo
- Publication number
- DE1966436C3 DE1966436C3 DE19691966436 DE1966436A DE1966436C3 DE 1966436 C3 DE1966436 C3 DE 1966436C3 DE 19691966436 DE19691966436 DE 19691966436 DE 1966436 A DE1966436 A DE 1966436A DE 1966436 C3 DE1966436 C3 DE 1966436C3
- Authority
- DE
- Germany
- Prior art keywords
- vaccine
- serum
- antigen
- agglutinogenic
- vaccines
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 229960005486 vaccine Drugs 0.000 title claims description 40
- 210000002966 serum Anatomy 0.000 title claims description 38
- 239000000427 antigen Substances 0.000 claims description 26
- 102000036639 antigens Human genes 0.000 claims description 26
- 108091007433 antigens Proteins 0.000 claims description 26
- 230000004523 agglutinating effect Effects 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 206010039438 Salmonella Infections Diseases 0.000 claims description 6
- 206010039447 salmonellosis Diseases 0.000 claims description 6
- 201000005702 Pertussis Diseases 0.000 claims description 4
- 201000008827 tuberculosis Diseases 0.000 claims description 4
- 206010008631 Cholera Diseases 0.000 claims description 3
- 208000010359 Newcastle Disease Diseases 0.000 claims description 3
- 206010035148 Plague Diseases 0.000 claims description 3
- 241000607479 Yersinia pestis Species 0.000 claims description 3
- 239000000725 suspension Substances 0.000 description 15
- 241000894006 Bacteria Species 0.000 description 11
- 230000001580 bacterial effect Effects 0.000 description 10
- 239000000047 product Substances 0.000 description 9
- 239000012071 phase Substances 0.000 description 8
- 241000700605 Viruses Species 0.000 description 7
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 230000004520 agglutination Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 235000013601 eggs Nutrition 0.000 description 5
- 229960004279 formaldehyde Drugs 0.000 description 5
- 235000019256 formaldehyde Nutrition 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 206010022000 influenza Diseases 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 244000052616 bacterial pathogen Species 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 241000711404 Avian avulavirus 1 Species 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000035931 haemagglutination Effects 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 230000000415 inactivating effect Effects 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 2
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 206010006500 Brucellosis Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241000607683 Salmonella enterica subsp. enterica serovar Pullorum Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000003837 chick embryo Anatomy 0.000 description 1
- 210000003711 chorioallantoic membrane Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| LU56161 | 1968-05-28 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DE1966436A1 DE1966436A1 (de) | 1972-12-07 |
| DE1966436B2 DE1966436B2 (de) | 1981-01-22 |
| DE1966436C3 true DE1966436C3 (de) | 1982-02-04 |
Family
ID=19725613
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19691966436 Expired DE1966436C3 (de) | 1968-05-28 | 1969-05-27 | Verwendung einer Antigen-Immunserum-Kombination als Impfstoff |
Country Status (10)
| Country | Link |
|---|---|
| AT (1) | AT293612B (enExample) |
| BE (1) | BE733615A (enExample) |
| CH (1) | CH513979A (enExample) |
| DE (1) | DE1966436C3 (enExample) |
| FR (1) | FR2009493A1 (enExample) |
| GB (1) | GB1248097A (enExample) |
| IE (1) | IE33123B1 (enExample) |
| IT (1) | IT1053697B (enExample) |
| LU (1) | LU56161A1 (enExample) |
| NL (1) | NL6908122A (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2949031A1 (de) * | 1978-12-15 | 1980-07-17 | Sandoz Ag | Vakzine |
| FR2527447A1 (fr) * | 1982-05-27 | 1983-12-02 | Leguern Jacques | Procede d'amelioration metabolique par autohemostimulation potentialisee |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE231055C (enExample) * | ||||
| DE231056C (enExample) * | ||||
| GB150334A (en) * | 1919-08-23 | 1921-06-30 | Elektro Osmose Ag | Manufacture of specific vaccines |
| GB708976A (en) * | 1952-02-16 | 1954-05-12 | Fort Dodge Lab Inc | Vaccine and process for manufacturing the same |
-
1968
- 1968-05-28 LU LU56161D patent/LU56161A1/xx unknown
-
1969
- 1969-05-27 DE DE19691966436 patent/DE1966436C3/de not_active Expired
- 1969-05-27 BE BE733615D patent/BE733615A/xx not_active IP Right Cessation
- 1969-05-27 IE IE72769A patent/IE33123B1/xx unknown
- 1969-05-27 GB GB2682269A patent/GB1248097A/en not_active Expired
- 1969-05-28 IT IT1743769A patent/IT1053697B/it active
- 1969-05-28 NL NL6908122A patent/NL6908122A/xx unknown
- 1969-05-28 FR FR6917294A patent/FR2009493A1/fr not_active Withdrawn
- 1969-05-28 AT AT505369A patent/AT293612B/de not_active IP Right Cessation
- 1969-05-28 CH CH820569A patent/CH513979A/fr not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| IE33123B1 (en) | 1974-03-20 |
| NL6908122A (enExample) | 1969-12-02 |
| CH513979A (fr) | 1971-10-15 |
| FR2009493A1 (enExample) | 1970-02-06 |
| IE33123L (en) | 1969-11-28 |
| DE1966436B2 (de) | 1981-01-22 |
| IT1053697B (it) | 1981-10-10 |
| BE733615A (enExample) | 1969-11-27 |
| LU56161A1 (enExample) | 1970-01-14 |
| DE1926817A1 (de) | 1970-01-15 |
| DE1966436A1 (de) | 1972-12-07 |
| AT293612B (de) | 1971-10-25 |
| GB1248097A (en) | 1971-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AT408615B (de) | Neue influenzavirus-impfstoffzusammensetzung | |
| DE3853854T2 (de) | Vakzin gegen Neisseria meningitidis Gruppe-B, Gammaglobulin und Transferfaktor. | |
| DE3911442A1 (de) | Impfstoff-praeparation | |
| DE69232969T2 (de) | Methode zur herstellung von gram-negativen bakteriellen vakzinen | |
| EP0173241B1 (de) | Vakzine zur Behandlung der Harnwegsinfektionen | |
| DE2603321A1 (de) | Emulsion auf der grundlage eines stoffwechselfaehigen pflanzlichen oels und wasser | |
| DE2735411A1 (de) | Verfahren zur herstellung von acellulaeren vaccinen und nach diesem verfahren gewonnene vaccine | |
| DE3882781T2 (de) | Impfstoff gegen Pasteurella. | |
| DE2823750C3 (de) | Verfahren zur Gewinnung mindestens eines Hydrolyseprodukts eines Endotoxins von Bordetella Pertussis | |
| DE2360118A1 (de) | Vakzinen gegen ferkel-colibacillose und verfahren zu ihrer herstellung | |
| DE1966436C3 (de) | Verwendung einer Antigen-Immunserum-Kombination als Impfstoff | |
| DE2445819A1 (de) | Verfahren zur herstellung stabiler, gegen seruminhibitoren resistenter h tief 3 n tief 2 -influenzavirusstaemme und diese virusstaemme enthaltende vakzinen | |
| DE1617545C2 (de) | Verwendung von informatorischer Ribonucleinsäure als Vaccine | |
| DE1265916B (de) | Verfahren zur Herstellung eines Brucellose-Impfstoffs | |
| CH639667A5 (de) | Verfahren zur herstellung von peptidkomplexen aus dns-haltigen organismen. | |
| Mackie | Non-Specific Stimulation of a Natural Antibody. | |
| DE2815758C3 (de) | Peptidkomplexe aus DNS-haltigen Organismen | |
| DE2141901C3 (de) | Steriler Impfstoff, der abgetötete Organismen des genus Fusiformis nodosus enthält | |
| DE1926817C (de) | Brucellose Antigene enthaltende Vaccme | |
| DE2225548A1 (de) | Intravenoes vertraegliche staupe- und hepatitisvaccine | |
| DE1617288C (de) | Verfahren zur Herstellung eines Grippe virusimpfstoffs | |
| DE1007473B (de) | Verfahren zur Herstellung eines Poliomyelitis-Impfstoffes | |
| DE1617549C (de) | Verfahren zur Herstellung eines Impf Stoffs gegen Tollwut | |
| AT226372B (de) | Dessaggregiertes Gammaglobulin und Verfahren zu seiner Herstellung | |
| AT234902B (de) | Verfahren zur Herstellung einer Vaccine gegen Staupe |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AC | Divided out of |
Ref country code: DE Ref document number: 1926817 Format of ref document f/p: P |
|
| C3 | Grant after two publication steps (3rd publication) | ||
| 8328 | Change in the person/name/address of the agent |
Free format text: BERENDT, T., DIPL.-CHEM. DR., PAT.-ANW., 8000 MUENCHEN |
|
| 8339 | Ceased/non-payment of the annual fee |